Abstract
This study explores the perceptions of stakeholders regarding the pilot Chief Pharmacist System (CPS) in China. The attitudes of most participants were found to be positive toward the CPS, noting its potential to enhance the prestige of hospital pharmacy departments, improve the quality of pharmaceutical care services, and promote rational drug use. However, the study also identifies critical barriers—such as unclear administrative authority and inadequate compensation—that must be addressed to ensure the system's long-term success.
Introduction
For decades, hospital pharmacy departments in China functioned primarily as logistics centers focused on drug procurement and distribution. This model was disrupted by the 2009 "Zero-markup" drug policy, which prohibited hospitals from profiting on medicine sales, effectively stripping pharmacy departments of their traditional revenue-generating role. Consequently, there has been an urgent need to pivot toward "pharmaceutical care," focusing on clinical services like prescription review and medication monitoring.
The Chief Pharmacist System (CPS) was introduced as a pilot leadership model to drive this transition. While implemented in several regions, qualitative research into how the system is perceived by those running it—pharmacists and government officials—has been limited. This study aims to fill that gap by exploring the effectiveness and hurdles of the CPS reform.
Methods
The researchers conducted a multicenter exploratory qualitative study using semi-structured interviews with 18 key stakeholders. The participants included 11 Chief Pharmacists, 5 Pharmacy Directors, and 2 government representatives from five distinct regions: Shaanxi, Xinjiang, Shandong, Guangdong, and Beijing.
The team employed a thematic analysis approach, using purposive sampling to reach a "saturation point" where no new themes emerged. Interviews were transcribed, de-identified, and coded using NVivo version 12 Plus software. The study primarily focused on 16 hospitals, comprising 13 tertiary and 3 secondary institutions.
Key Insights and Results
The analysis revealed a broad consensus that the CPS is a timely and necessary reform. The findings were categorized into several major themes, ranging from the role of the Chief Pharmacist to the specific barriers hindering the system's implementation.
Professional Prestige and Clinical Impact
A significant finding was that the CPS enhances the professional identity and prestige of the pharmacy department. Participants noted that the system allows pharmacists to interact with physicians and patients as clinical peers rather than mere dispensers. This shift is reflected in improved clinical outcomes, such as higher intervention rates where pharmacists meet with doctors to correct irrational prescribing patterns, particularly for high-risk drugs like antibacterials.
Administrative and Economic Challenges
Despite the positive reception, the study highlighted a "Two-Headed" leadership problem. There is often a confusing overlap between the clinical/managerial role of the "Chief Pharmacist" and the traditional administrative role of the "Director of the Pharmacy Department." This lack of clear authority can lead to organizational friction.
Furthermore, a significant salary gap remains. While the CPS demands high-level clinical expertise, financial rewards have not consistently followed. Although some regions have introduced consultation fees (e.g., 26 RMB for a Chief Pharmacist), many participants argued that compensation is still too low to attract and retain top-tier talent.
Conclusion and Future Directions
The CPS represents a vital step in transitioning Chinese hospital pharmacies into clinical care centers. While it has successfully improved the quality of pharmaceutical services, its future depends on resolving administrative ambiguities, improving staff training, and establishing better insurance and compensation policies.
Limitations of this study include a small sample size and a focus on management-level perspectives. Future research should incorporate the views of front-line junior pharmacists, physicians, and patients to provide a more holistic view of the system's impact across the healthcare landscape.
Summary updated